Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece [Corrigendum]
Vassilis Fragoulakis,1 Efklidis Raptis,2 Elli Vitsou,2 Nikolaos Maniadakis11Health Services Organization and Management, National School of Public Health, 2Pfizer Hellas, Athens, Greece The authors apologize that the following errors appear in their paper:• Page 75, right column, l...
Main Authors: | Fragoulakis V, Raptis E, Vitsou E, Maniadakis N |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-03-01
|
Series: | ClinicoEconomics and Outcomes Research |
Online Access: | http://www.dovepress.com/corrigendum-annual-biologic-treatment-cost-for-new-and-existing-p-peer-reviewed-article-CEOR |
Similar Items
-
Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
by: Fragoulakis V, et al.
Published: (2015-01-01) -
Estimating the long-term effects of in vitro fertilization in Greece: an analysis based on a lifetime-investment model
by: Fragoulakis V, et al.
Published: (2013-06-01) -
Self-reported prevalence of atherothrombosis in a general population sample of adults in Greece; A telephone survey
by: Fragoulakis Vasileios, et al.
Published: (2011-04-01) -
Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece
by: Fragoulakis V, et al.
Published: (2012-05-01) -
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
by: Ruggiero A, et al.
Published: (2023-11-01)